293 related articles for article (PubMed ID: 10771473)
1. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy.
Cho D; Kim TG; Lee W; Hwang YI; Cho HI; Han H; Kwon O; Kim D; Park H; Houh D
J Invest Dermatol; 2000 May; 114(5):928-34. PubMed ID: 10771473
[TBL] [Abstract][Full Text] [Related]
2. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
3. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
4. Effects of macrophage colony-stimulating factor and interleukin-2 administration on NK1.1(+) cells in mice.
Misawa E; Sakurai T; Yamada M; Hayasawa H; Motoyoshi K
Int J Immunopharmacol; 2000 Nov; 22(11):967-77. PubMed ID: 11090705
[TBL] [Abstract][Full Text] [Related]
5. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells.
Dobashi H; Seki S; Habu Y; Ohkawa T; Takeshita S; Hiraide H; Sekine I
Hepatology; 1999 Aug; 30(2):430-6. PubMed ID: 10421651
[TBL] [Abstract][Full Text] [Related]
6. IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma.
Jiang Q; Wei H; Tian Z
J Immunother; 2008; 31(6):555-62. PubMed ID: 18528299
[TBL] [Abstract][Full Text] [Related]
7. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.
Yeh KY; Pulaski BA; Woods ML; McAdam AJ; Gaspari AA; Frelinger JG; Lord EM
Cell Immunol; 1995 Oct; 165(2):217-24. PubMed ID: 7553886
[TBL] [Abstract][Full Text] [Related]
8. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
9. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
11. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells.
Tomura M; Zhou XY; Maruo S; Ahn HJ; Hamaoka T; Okamura H; Nakanishi K; Tanimoto T; Kurimoto M; Fujiwara H
J Immunol; 1998 May; 160(10):4738-46. PubMed ID: 9590219
[TBL] [Abstract][Full Text] [Related]
12. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
13. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2002 Sep; 119(3):541-8. PubMed ID: 12230493
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
[TBL] [Abstract][Full Text] [Related]
16. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
[TBL] [Abstract][Full Text] [Related]
18. B7.1 expression eliminates tumor resistance to IL-12 gene therapy.
Heise CP; Shi F; Albertini MR; Mahvi DM
Cancer Gene Ther; 2001 Feb; 8(2):118-27. PubMed ID: 11263527
[TBL] [Abstract][Full Text] [Related]
19. Booster effect of interleukin-2 on natural killer 1.1+ cells stimulated by administration of macrophage colony-stimulating factor in mice.
Misawa E; Sakurai T; Yamada M; Hayasawa H; Motoyoshi K
J Immunother; 2003; 26(1):21-30. PubMed ID: 12514426
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice.
Fujii H; Inobe M; Kimura F; Murata J; Murakami M; Onishi Y; Azuma I; Uede T; Saiki I
Int J Cancer; 1996 Apr; 66(2):219-24. PubMed ID: 8603815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
